Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

The present invention relates to a pharmaceutical composition for combined administration of melatonin and prostaglandin E.sub.2 (PGE.sub.2) for the treatment of intestinal epithelial injury diseases, and it is confirmed that when intestinal epithelial organoids are treated in combination with melatonin and PGE.sub.2, the expression of revival stem cell markers increases more than when the two substances are treated alone, and therefore it can be usefully used as a composition for preventing, treating or improving intestinal epithelial injury diseases.

The present invention relates to a pharmaceutical composition for combined administration of melatonin and prostaglandin E.sub.2 (PGE.sub.2) for the treatment of intestinal epithelial injury diseases, and it is confirmed that when intestinal epithelial organoids are treated in combination with melatonin and PGE.sub.2, the expression of revival stem cell markers increases more than when the two substances are treated alone, and therefore it can be usefully used as a composition for preventing, treating or improving intestinal epithelial injury diseases.

The invention provides a composition comprising one or more hydroxytryptamides and method of its use in the treatment of neurodegenerative disorders. The invention includes embodiments wherein the composition comprises caffeine and chlorogenic acids. The composition finds use in the treatment of Alzheimer's disease and Parkinson's disease, including providing neuroprotection against the advancement of the symptoms of these disorders.

The invention provides a composition comprising one or more hydroxytryptamides and method of its use in the treatment of neurodegenerative disorders. The invention includes embodiments wherein the composition comprises caffeine and chlorogenic acids. The composition finds use in the treatment of Alzheimer's disease and Parkinson's disease, including providing neuroprotection against the advancement of the symptoms of these disorders.

The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A.sub.2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A.sub.2 receptor antagonist to a patient in need thereof.

The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A.sub.2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A.sub.2 receptor antagonist to a patient in need thereof.